Breast cancer treatment has improved greatly over the years, and many patients now survive and live long lives after diagnosis.
However, one of the biggest challenges remains the risk that the cancer may return after treatment. Detecting this risk early can make a major difference in patient care.
A new study presented at the European Breast Cancer Conference has found that a simple blood test may help predict which patients are more likely to experience a relapse. The research was carried out by an international team of scientists from Belgium and Italy.
The study focuses on circulating tumor DNA, also known as ctDNA. This is genetic material released by cancer cells into the bloodstream. Even when a tumor appears to be gone, small amounts of cancer DNA can still be detected in blood samples.
The researchers studied 81 patients with early breast cancer who received treatment before surgery. This type of treatment, called neoadjuvant therapy, is commonly used to shrink tumors and improve surgical outcomes.
Blood samples were collected at several time points, including before treatment, after treatment, and during follow-up. The patients were then monitored for several years to see whether their cancer returned.
The findings showed that ctDNA was present in more than half of the patients at the start of the study. After treatment, this number dropped significantly. However, a small group of patients still had ctDNA in their blood even after completing therapy.
These patients were at much higher risk of cancer coming back. The study found that they were more than three times as likely to experience a relapse compared to patients without ctDNA.
One of the most striking results was that ctDNA could predict recurrence even when there were no visible signs of cancer after treatment. This suggests that ctDNA may be able to detect hidden disease that traditional methods cannot find.
The study also found that ctDNA was more often detected in patients with more aggressive types of breast cancer. This highlights its potential use in identifying high-risk patients who may need closer monitoring or additional treatment.
The researchers believe that ctDNA testing could help doctors make better decisions about patient care. For example, patients with positive ctDNA results might receive extra therapy after surgery, while those with negative results might avoid unnecessary side effects from additional treatment.
However, the researchers also emphasize that more work is needed before ctDNA testing becomes widely used. Larger clinical trials are required to confirm these results and to test whether treatment changes based on ctDNA actually improve outcomes.
There are also practical challenges, such as cost and access to testing, which need to be addressed before this approach can be used routinely in hospitals.
Despite these limitations, the study offers an exciting glimpse into the future of cancer care. It shows how advances in science can lead to more precise and personalized treatment strategies.
In conclusion, this research highlights the potential of a simple blood test to provide valuable information about cancer risk. While still in the early stages, it could one day help doctors detect relapse earlier and improve survival for patients with breast cancer.
If you care about breast cancer, please read studies about a major cause of deadly breast cancer, and this daily vitamin is critical to cancer prevention.
For more information about cancer, please see recent studies that new cancer treatment could reawaken the immune system, and results showing vitamin D can cut cancer death risk.
Source: Institut Jules Bordet.
